Apellis Pharmaceuticals, Inc. 4

Leslie Meltzer, Chief Research and Development of Apellis Pharmaceuticals, Inc., had 107,024 common shares, multiple RSU awards (totaling 129,634 shares), and a vested stock option for 92,592 shares cashed out or converted into cash and contingent value rights in connection with Biogen’s acquisition of Apellis.

On May 14, 2026, Chief Research and Development officer Leslie Meltzer’s equity in Apellis Pharmaceuticals, Inc. was fully cashed out in connection with the closing of Biogen Inc.’s acquisition of Apellis. A total of 107,024 shares of common stock previously held directly were disposed of for cash and contingent value rights under the merger consideration. In addition, multiple restricted stock unit awards covering 22,610 shares, 45,220 shares and 61,804 shares of common stock, respectively, were cancelled and converted into the right to receive the $41.00 per‑share cash merger price plus one CVR per underlying share, subject to continued service-based vesting. Separately, an outstanding stock option for 92,592 shares with a $27.93 exercise price was cancelled and converted into a cash payment equal to the in‑the‑money value (the excess of $41.00 over $27.93 per share) plus one CVR per underlying share. Following these merger-related transactions, Meltzer no longer holds Apellis equity securities, and Apellis became a wholly owned subsidiary of Biogen.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224620

Alert Tier

7